NASDAQ:BMEA Biomea Fusion (BMEA) Stock Forecast, Price & News $12.89 +0.18 (+1.42%) (As of 10/3/2023 ET) Add Compare Share Share Today's Range$12.32▼$13.1950-Day Range$12.71▼$22.2552-Week Range$6.04▼$43.69Volume360,413 shsAverage Volume555,673 shsMarket Capitalization$459.27 millionP/E RatioN/ADividend YieldN/APrice Target$43.88 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Biomea Fusion MarketRank™ ForecastAnalyst RatingModerate Buy2.89 Rating ScoreUpside/Downside240.4% Upside$43.88 Price TargetShort InterestBearish28.76% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.89Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($3.42) to ($3.76) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.82 out of 5 starsMedical Sector775th out of 966 stocksPharmaceutical Preparations Industry360th out of 445 stocks 3.4 Analyst's Opinion Consensus RatingBiomea Fusion has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $43.88, Biomea Fusion has a forecasted upside of 240.4% from its current price of $12.89.Amount of Analyst CoverageBiomea Fusion has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted28.76% of the float of Biomea Fusion has been sold short.Short Interest Ratio / Days to CoverBiomea Fusion has a short interest ratio ("days to cover") of 13.5, which indicates bearish sentiment.Change versus previous monthShort interest in Biomea Fusion has recently increased by 4.69%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldBiomea Fusion does not currently pay a dividend.Dividend GrowthBiomea Fusion does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BMEA. Previous Next 2.7 News and Social Media Coverage News SentimentBiomea Fusion has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.65 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Biomea Fusion this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for BMEA on MarketBeat in the last 30 days. This is a decrease of -17% compared to the previous 30 days.MarketBeat Follows1 people have added Biomea Fusion to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Biomea Fusion insiders have not sold or bought any company stock.Percentage Held by Insiders26.27% of the stock of Biomea Fusion is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions93.68% of the stock of Biomea Fusion is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Biomea Fusion are expected to decrease in the coming year, from ($3.42) to ($3.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biomea Fusion is -3.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biomea Fusion is -3.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiomea Fusion has a P/B Ratio of 3.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Biomea Fusion (NASDAQ:BMEA) StockBiomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.Read More BMEA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BMEA Stock News HeadlinesSeptember 28, 2023 | markets.businessinsider.comPositive Indicators Drive Buy Rating for Biomea Fusion: Promising T2D Treatment and Favorable Efficacy OutcomesSeptember 28, 2023 | finance.yahoo.comBiomea Fusion Announces FDA and Health Canada Clearance of the Expansion Cohorts of the Ongoing COVALENT-111 Phase II StudyOctober 4, 2023 | Edge On The Street (Ad)The Strategic Gold Play You Haven't Heard AboutExperts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure. September 20, 2023 | seekingalpha.comNavigating Biomea Fusion's Labyrinth: From Blood To Beta CellsAugust 31, 2023 | finance.yahoo.comBiomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical OfficerAugust 1, 2023 | markets.businessinsider.comH.C. Wainwright Remains a Buy on Biomea Fusion (BMEA)July 31, 2023 | finance.yahoo.comBiomea Fusion Reports Second Quarter 2023 Financial Results and Corporate HighlightsJuly 27, 2023 | msn.comScotiabank Initiates Coverage of Biomea Fusion (BMEA) with Sector Outperform RecommendationOctober 4, 2023 | Wall Street Fundamentals (Ad)Would Buffett Approve of This Growth Strategy?Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.July 25, 2023 | markets.businessinsider.com14 Analysts Have This to Say About Biomea FusionJuly 24, 2023 | markets.businessinsider.comBiomea Fusion (BMEA) Gets a Buy from H.C. WainwrightJuly 24, 2023 | markets.businessinsider.comWhy Biomea Fusion Stock Is Falling Today?July 24, 2023 | finance.yahoo.comBMF-219 Induces Complete Responses in Target Acute Myeloid Leukemia (AML) Patient PopulationJuly 16, 2023 | seekingalpha.comBiomea Fusion: Potential Cure For Diabetes, Initiating With A BuyJuly 13, 2023 | finance.yahoo.comWe Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth CarefullyJuly 6, 2023 | msn.comBiomea Fusion (BMEA) Price Target Increased by 30.85% to 56.25July 4, 2023 | theglobeandmail.comBMEA ALERT: The Law Offices of Vincent Wong Investigate Biomea Fusion, Inc. for Potential Violations of Securities LawsJune 27, 2023 | msn.comJP Morgan Maintains Biomea Fusion (BMEA) Overweight RecommendationJune 26, 2023 | businesswire.comINVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Biomea Fusion, Inc. and Encourages Investors with Losses to Contact the FirmJune 26, 2023 | msn.comJefferies Reconsiders, BMEA Plummets after Sour Diabetes Drug DataJune 26, 2023 | markets.businessinsider.comWhat 18 Analyst Ratings Have To Say About Biomea FusionJune 26, 2023 | msn.comJefferies downgrades Biomea to hold amid new data on diabetes drugJune 26, 2023 | msn.comBiomea Soars on Promising Phase 2 Data in Type 2 DiabetesJune 26, 2023 | markets.businessinsider.comPiper Sandler Reaffirms Their Buy Rating on Biomea Fusion (BMEA)June 26, 2023 | markets.businessinsider.comBiomea Fusion Stock Is Trading Higher Today - Here's WhyJune 23, 2023 | finance.yahoo.comBiomea Fusion Presents Positive Clinical Data from the Initial Cohorts of the Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes Mellitus at the American Diabetes Association (ADA) 83rd Scientific Sessions; 100 mg Cohort 3 Demonstrated a 90% Response Rate and 70% Maintained or Improved Time in (Normal Glucose) Range, While Off-TreatmentJune 20, 2023 | finance.yahoo.comBiomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes at ADA 2023See More Headlines Receive BMEA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biomea Fusion and its competitors with MarketBeat's FREE daily newsletter. Email Address BMEA Company Calendar Last Earnings7/31/2023Today10/04/2023Next Earnings (Estimated)11/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BMEA CUSIPN/A CIK1840439 Webwww.biomeafusion.com Phone650-980-9099FaxN/AEmployees94Year FoundedN/APrice Target and Rating Average Stock Price Forecast$43.88 High Stock Price Forecast$60.00 Low Stock Price Forecast$22.00 Forecasted Upside/Downside+240.4%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($3.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-81,830,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-74.75% Return on Assets-64.28% Debt Debt-to-Equity RatioN/A Current Ratio15.74 Quick Ratio15.74 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.69 per share Price / Book3.49Miscellaneous Outstanding Shares35,630,000Free Float26,271,000Market Cap$459.27 million OptionableNot Optionable Beta-1.06 10 Best Stocks to Own in 2023Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Thomas Andrew Butler (Age 42)Co-Founder, Chairman & CEO Comp: $921.14kMr. Ramses M. Erdtmann (Age 60)Co-Founder, Pres, COO & Director Comp: $659.53kMr. Franco Valle (Age 42)CFO & Principal Accounting Officer Comp: $651.77kMr. Heow Tan (Age 64)Chief Technology & Quality Officer Ms. Naomi CretcherChief People OfficerDr. Thorsten Kirschberg Ph.D. (Age 53)Exec. VP of Chemistry Dr. Stephan Morris M.D.Chief Devel. OfficerMr. Ravi UpasaniExec. VP of Intellectual PropertyDr. Juan Pablo Frias M.D.Chief Medical Officer & Member of Scientific Advisory BoardMore ExecutivesKey CompetitorsAvidity BiosciencesNASDAQ:RNAOlema PharmaceuticalsNASDAQ:OLMATheravance BiopharmaNASDAQ:TBPHHarrow HealthNASDAQ:HROWRepare TherapeuticsNASDAQ:RPTXView All CompetitorsInsiders & InstitutionsPerceptive Advisors LLCBought 391,441 shares on 8/24/2023Ownership: 2.011%California State Teachers Retirement SystemBought 26,829 shares on 8/21/2023Ownership: 0.075%Osaic Holdings Inc.Bought 9,859 shares on 8/21/2023Ownership: 0.028%GTS Securities LLCBought 17,168 shares on 8/16/2023Ownership: 0.048%Royal Bank of CanadaBought 8,128 shares on 8/15/2023Ownership: 0.023%View All Insider TransactionsView All Institutional Transactions BMEA Stock - Frequently Asked Questions Should I buy or sell Biomea Fusion stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biomea Fusion in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BMEA shares. View BMEA analyst ratings or view top-rated stocks. What is Biomea Fusion's stock price forecast for 2023? 9 Wall Street analysts have issued 12-month price targets for Biomea Fusion's shares. Their BMEA share price forecasts range from $22.00 to $60.00. On average, they predict the company's share price to reach $43.88 in the next year. This suggests a possible upside of 240.4% from the stock's current price. View analysts price targets for BMEA or view top-rated stocks among Wall Street analysts. How have BMEA shares performed in 2023? Biomea Fusion's stock was trading at $8.43 at the beginning of the year. Since then, BMEA stock has increased by 52.9% and is now trading at $12.89. View the best growth stocks for 2023 here. When is Biomea Fusion's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023. View our BMEA earnings forecast. How were Biomea Fusion's earnings last quarter? Biomea Fusion, Inc. (NASDAQ:BMEA) posted its quarterly earnings results on Monday, July, 31st. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.86) by $0.16. What ETF holds Biomea Fusion's stock ? Invesco Dorsey Wright Healthcare Momentum ETF holds 113,300 shares of BMEA stock, representing 1.44% of its portfolio. When did Biomea Fusion IPO? (BMEA) raised $120 million in an initial public offering on Friday, April 16th 2021. The company issued 7,500,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Piper Sandler served as the underwriters for the IPO. What is Biomea Fusion's stock symbol? Biomea Fusion trades on the NASDAQ under the ticker symbol "BMEA." How do I buy shares of Biomea Fusion? Shares of BMEA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Biomea Fusion's stock price today? One share of BMEA stock can currently be purchased for approximately $12.89. How much money does Biomea Fusion make? Biomea Fusion (NASDAQ:BMEA) has a market capitalization of $459.27 million. The company earns $-81,830,000.00 in net income (profit) each year or ($3.32) on an earnings per share basis. How can I contact Biomea Fusion? The official website for the company is www.biomeafusion.com. The company can be reached via phone at 650-980-9099 or via email at vsandwick@biomeafusion.com. This page (NASDAQ:BMEA) was last updated on 10/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomea Fusion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.